Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic …
Rigel Provides Business Update and 2025 Outlook
Jan 13, 2025 · Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of …
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results …
Mar 4, 2025 · Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of …
Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL)
Feb 25, 2025 · Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of …
Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with …
Rigel Announces R289 Granted Fast Track Designation by the FDA …
Dec 2, 2024 · SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused …
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for ...
Oct 24, 2024 · Healthcare providers and patients are encouraged to report adverse events in patients taking GAVRETO to the Rigel Medical Communications Center at 1-800-983-1329 or …
Rigel Announces R289 Granted Orphan Drug Designation by the …
Jan 9, 2025 · SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused …
Rigel Reports First Quarter 2024 Financial Results and Provides ...
May 7, 2024 · First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA® net product sales of $4.9 million Expanded …
Rigel Reports Third Quarter 2024 Financial Results and Provides ...
SOUTH SAN FRANCISCO, Calif., Nov. 7, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic …